EXAS
Exact Sciences CorporationNASDAQHealthcare$104.91+0.00%ClosedMarket Cap: $20.03B
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
8.29
P/S
6.17
EV/EBITDA
506.73
DCF Value
$75.91
FCF Yield
1.8%
Div Yield
0.0%
Margins & Returns
Gross Margin
69.7%
Operating Margin
-6.2%
Net Margin
-6.4%
ROE
-8.5%
ROA
-8.1%
ROIC
-4.1%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $878.4M | 70.1% | $-76.7M | $-86.0M | $-0.45 | — |
| FY 2025 | $3.25B | 69.7% | $-99.1M | $-207.9M | $-1.10 | — |
| Q3 2025 | $850.7M | 68.6% | $-25.5M | $-19.6M | $-0.10 | — |
| Q2 2025 | $811.1M | 69.3% | $-2.1M | $-1.2M | $-0.01 | — |
| Q1 2025 | $706.8M | 70.8% | $-96.0M | $-101.2M | $-0.54 | — |
| Q4 2024 | $713.4M | 60.2% | $-876.4M | $-864.6M | $-4.67 | — |
| FY 2024 | $2.76B | 69.5% | $-1.05B | $-1.03B | $-5.59 | — |
| Q3 2024 | $708.7M | 69.4% | $-39.4M | $-38.2M | $-0.21 | — |
| Q2 2024 | $699.3M | 69.8% | $-26.3M | $-15.8M | $-0.09 | — |
| Q1 2024 | $637.5M | 70.0% | $-106.7M | $-110.2M | $-0.60 | — |
| Q4 2023 | $646.9M | 73.4% | $-67.8M | $-49.8M | $-0.27 | — |
| FY 2023 | $2.50B | 70.5% | $-215.0M | $-204.1M | $-1.13 | — |